Mubadala Will Create New Healthcare Company With G42
Posted on 04/18/2023
Abu Dhabi’s US$ 7 billion Mubadala Investment Company and G42, Abu Dhabi-based AI technology holding group, have announced the launch of M42, a technology integrated healthcare company that will merge G42 Healthcare and Mubadala Health. A joint statement declared: “M42 combines G42 Healthcare’s unique medical and data-centric technologies with Mubadala Health’s world-class patient services and state-of-the-art facilities to provide the highest level of personalized, precise, and preventative care. Operating at the forefront of medical development, M42 is set to transform the way care is delivered, bridging the gap between the latest healthtech advancements and the clinical outcomes patients receive.”
Leadership will be the responsibility of Hasan Jasem Al Nowais, CEO and Managing Director of M42. M42 will continue to look for opportunities for global expansion and partnerships with pharmaceutical, healthcare, and technology companies. Things are looking good according to the M42: “As we launch M42, we are excited to impactfully disrupt the global healthcare industry. Our vision is to transform lives through innovation by providing personalized, and precise patient care. We are confident that through our operating companies, M42 will create a future in which dedicated healthcare professionals are empowered by the latest technology to optimize patient outcomes.” M42 already owns Amana Healthcare, Biogenix Labs, Danat Al Emarat, HealthPoint Hospital, the HealthPlus network, Moorfields Eye Hospital Abu Dhabi, Imperial College London Diabetes Centre, Insights Research Organization & Solutions (IROS), Omics Center of Excellence and The National Reference Laboratory.